Sarissa Capital Management
- Company typePrivate
- Founded2014
- HeadquartersGreenwich, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Sarissa Capital Management does
Sarissa Capital Management LP is a privately-held investment management firm headquartered at 660 Steamboat Road, Greenwich, Connecticut, operating as a limited partnership under US jurisdiction. Founded around 2013-2014, the firm is led by Alex Denner as Founding Partner and Chief Investment Officer, with Eric Vincent serving as President. The firm employs between 11 and 50 people, consistent with a focused, principal-driven activist investment model.
The firm specializes in healthcare and life sciences investing, with a particular emphasis on clinical-stage biotechnology companies facing strategic challenges, regulatory setbacks, or depressed valuations. Its investment approach targets asymmetric risk-reward opportunities in companies with meaningful cash positions and late-stage clinical programs — positioning them as potential turnaround stories. A disclosed recent example is the Q4 2025 establishment of a new equity position in Biohaven Ltd. (513,184 shares, approximately $5.79 million), a clinical-stage biotech with an obesity candidate expected to deliver data in H2 2026 and a $322 million cash balance (plus $178.9 million raised post-year-end).
Revenue is generated through the standard hedge fund model: investment management fees and carried interest on fund capital deployed across portfolio companies. The firm's product set includes core investment management services to fund investors, supplemented by regulatory compliance artifacts such as PFIC (Passive Foreign Investment Company) Annual Information Statements for a legacy SPAC vehicle (Sarissa Capital Acquisition Corp – Class A). Pricing, AUM, and LP composition are not publicly disclosed.
Sarissa Capital Management firmographics
Firmographics- Name
- Sarissa Capital Management
- Legal name
- Sarissa Capital Management LP
- Website
- https://sarissacap.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Sarissa Capital Management industry classification
Industry- Product category
- Hedge Fund / Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Small-Cap Equity (Active) (FSAAAIAC)
- akta.pro secondary industry
- Institutional Separate Accounts & SMAs (Mandates) (FSAAAGAL)
Keywords
Where Sarissa Capital Management is headquartered
LocationHeadquarters
- HQ city
- Greenwich
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sarissa Capital Management business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Investment Management Fees and Carried Interest: As a registered investment advisor/hedge fund, Sarissa Capital generates returns through investment in portfolio companies. The firm acquires equity positions in target companies and generates returns through appreciation in portfolio company values, realized gains upon exits, and management/carried interest fees charged to fund investors.
Sarissa Capital Management product offering
Product offeringCore offering
Sarissa Capital Management LP is a private investment management firm that provides investment management services with a concentrated focus on the healthcare and life sciences sectors, particularly clinical-stage biotechnology companies. The firm pursues activist investing strategies and portfolio company value creation, targeting turnaround opportunities in companies with depressed valuations due to clinical setbacks or FDA rejections. Capital is deployed through private equity and hedge fund structures to limited partner investors.
Product overview
Sarissa Capital Management LP is a private investment management firm that provides investment management services with a focus on healthcare and life sciences sectors. The firm offers its core investment management services to investors, supplemented by regulatory compliance products such as PFIC Annual Information Statements. The website serves as a corporate information portal providing access to investment firm contact details, downloadable financial statements, and regulatory documentation.
Differentiator
Problem solved
Functional benefit
Products and services
- Sarissa Capital Investment Management Services Private investment management services targeting healthcare and life sciences companies, with a focus on activist investing strategies and portfolio company value creation. The service is offered to fund investors (limited partners) and involves acquiring equity positions in target companies and generating returns through appreciation in portfolio company values and realized gains upon exits.
- PFIC Annual Information Statement Passive Foreign Investment Company (PFIC) annual reporting documentation provided to fund investors, containing tax-related information and financial statements for compliance purposes. Available for download in 2021 and 2022 versions on the firm website.
Companies that use Sarissa Capital Management
Customer profileIdeal customer profiles2 records
Sarissa Capital Management technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Sarissa Capital Management partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights3 records
Sarissa Capital Management competitors and assessment
Company assessmentDirect peers
- Icahn Partners: Pioneer activist fund where Sarissa founder Alex Denner previously served as senior portfolio manager. Comparable to Sarissa in activist style, with overlap in healthcare targets including biotech.
- Baker Bros. Advisors: Long-running, healthcare-specialist investment firm that takes concentrated equity positions in biotech and life sciences companies. Highly comparable to Sarissa in its focus on biotech-focused, fundamental-driven equity ownership.
- OrbiMed Advisors: Large, healthcare-dedicated investment firm covering public and private biotech, medtech, and healthcare services. Comparable to Sarissa in its single-sector focus, though it operates across more strategies and stages.
- Deerfield Management: Healthcare-focused investment firm combining public equity, private capital, and venture-style structures. Comparable to Sarissa in its deep healthcare focus and willingness to engage with management on strategy.
- ValueAct Capital: Established activist fund taking large, engaged positions in mid- and large-cap public companies. Comparable to Sarissa in activist posture, though broader across sectors.
- EcoR1 Capital: Biotech-focused fund that invests across public and private clinical-stage companies, often taking activist or engaged positions. Comparable to Sarissa in sector specialization and stage of investment.
- Third Point: Multi-strategy fund with a significant activist sleeve that engages publicly with portfolio companies. Comparable to Sarissa in its activist toolkit and willingness to take concentrated positions.
- RA Capital Management: Healthcare-focused crossover investor with deep biotech exposure and active engagement with portfolio company management. Closely comparable to Sarissa's clinical-stage biotech equity strategy.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Sarissa Capital Management social profiles
Digital presenceSarissa Capital Management financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sarissa Capital Management leadership team
Management profileNumber of profiles
Profiles2 records
Sarissa Capital Management funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sarissa Capital Management M&A and investment
M&A and investmentM&A
Investments6 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sarissa Capital Management
What does Sarissa Capital Management do?
Sarissa Capital Management LP is a private investment management firm that provides investment management services with a concentrated focus on the healthcare and life sciences sectors, particularly clinical-stage biotechnology companies. The firm pursues activist investing strategies and portfolio company value creation, targeting turnaround opportunities in companies with depressed valuations due to clinical setbacks or FDA rejections. Capital is deployed through private equity and hedge fund structures to limited partner investors.
Is Sarissa Capital Management a public or private company?
Sarissa Capital Management is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Sarissa Capital Management founded?
Sarissa Capital Management was founded in 2014. It employs 11 to 50 people.
Where is Sarissa Capital Management based?
Sarissa Capital Management is headquartered in Greenwich, United States, in the North America region.
How does Sarissa Capital Management make money?
One revenue line is on record: investment Management Fees and Carried Interest.
Who are Sarissa Capital Management's main competitors?
Direct peers on record are Icahn Partners, Baker Bros. Advisors, OrbiMed Advisors, Deerfield Management, ValueAct Capital, EcoR1 Capital, Third Point and RA Capital Management.
Does Sarissa Capital Management have an API?
No public API is recorded for Sarissa Capital Management.
What industry is Sarissa Capital Management in?
Sarissa Capital Management's product category is Hedge Fund / Investment Management. Its primary akta.pro industry code is FSAAAIAC, Small-Cap Equity (Active), with a secondary code of FSAAAGAL, Institutional Separate Accounts & SMAs (Mandates). Its NAICS code is 523940 and its SIC code is 6282.